# Processing report — Sinha Gul 2024

## Activated macros
- `@ATOM`
- `@SEA`

## Source
- Title: The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis
- Authors: Tanya Sinha; Ushna Gul; Nawabzada Nadir Babar; Farhan Israr; Aqsa A. Butt; Sandipkumar S. Chaudhari; Hamza Maqbool; Adil Amin
- Journal: Cureus
- Published: 19 September 2024
- DOI: 10.7759/cureus.69711
- PMID: 39429324
- Source file: `cureus-0016-00000069711.pdf`
- SHA-256: `ac8db02bf4a4907856394d006878ffe111ef433691e01016fa50aa5e5390862b`
- Shared publication ID: `9071c09b-9824-5c5f-b9f9-6284a92d9fca`

## ATOM
- LiteratureAtoms: **74**
- Counts by kind: author_conclusion=3, comparator_description=1, conflict_of_interest=1, eligibility_criterion=5, funding_disclosure=1, intervention_description=2, limitation=4, method=16, other=5, outcome_definition=5, population_description=3, qualitative_result=12, quantitative_result=15, study_objective=1
- Pydantic structural validation: **PASS**
- JSON Schema validation: **PASS**
- Sufficiency validation: **PASS**
- Sufficiency errors: **0**
- Sufficiency warnings: **0**
- Duplicate atom IDs: **0**

### Source consistency flags preserved
1. Results prose states seven observational studies and five RCTs, while Table 1 labels six observational studies and six RCTs. Petrie et al. 2020 appears in both Table 2 and Table 3.
2. Methods states funnel plots were used to assess small-study effects, while Limitations and Table 6 state publication bias could not be assessed because fewer than 10 studies contributed to each outcome.
3. Hospitalization-for-heart-failure prose reports empagliflozin versus dapagliflozin RR 1.02 (95% CI 0.84-1.24), whereas Figure 6 and Table 4 report 1.23 as the upper bound.
4. Table 6 certainty labels are internally difficult to reconcile with displayed inconsistency/imprecision judgments.
5. Wiviott 2019 and Zelniker 2020 are separate included entries despite matching dapagliflozin/placebo arm sizes and follow-up; Zelniker is explicitly a DECLARE-TIMI 58 analysis, raising overlapping-population risk.

## SEA
- Existing SEA artifact source-reconciled during lifecycle repair.
- Main-text figures reconciled: **6/6**
- Tables reconciled: **6/6**
- SEA QA: **PASS**
- Verdict: **Do not use for practice as a standalone source; retain as a hypothesis-generating comparative synthesis and source map.**

## Reference task queue
- Bibliography entries: **32**
- Queue ordering: source reference order
- Priority assignment: P0 direct/included comparative evidence, P1 important supporting evidence/guidance, P2 background/context.
- External bibliographic correction: not performed.

## Lifecycle repair — 2026-08-23
The prior output-location note claimed this source had already been moved to Processed, but the source folder remained active and ATOM JSON outputs were absent from the Drive JSON subfolder. This repair restores the JSON package, adds the requested reference task queue, verifies the existing SEA artifact, and closes the source lifecycle by moving the source folder to Processed.
